Hazardous waste characteristics and standard management approaches

2022 ◽  
pp. 145-164
Author(s):  
Gaurav Singh ◽  
P.K.S. Yadav
Author(s):  
Patrick J. Neligan ◽  
John G. Laffey

Pregnant patients constitute less than 1% of intensive care unit admissions, and fewer than 1% of obstetric patients become critically ill. Critical illness may result from pregnancy-specific diseases, diseases that pregnancy predisposes to, or are co-incidental to pregnancy. The presence of a second patient—the foetus—may necessitate adjustments to therapeutic and supportive strategies. However, the foetus is generally robust despite maternal illness. The physiological changes of pregnancy are significant, but may delay the diagnosis of critical illness, requiring modifications to standard management approaches. These include increases in minute ventilation, resulting in a ‘low normal’ PaCO2, a reduction in mean arterial pressure, but increased heart rate, low serum creatinine, relative hypoglycaemia, relative leukocytosis, and reduced lower oesophageal sphincter tone. Pre-eclampsia is a disease of the uteroplacental unit that results in abnormal maternal physiology. Pregnant women are at risk for acute respiratory distress syndrome, due to gastropulmonary aspiration and increased risk of community-acquired pneumonia, sepsis, principally of the genito-urinary system, and thromboembolic disease.


2013 ◽  
Vol 16 (3) ◽  
pp. 566-575 ◽  
Author(s):  
Young-Yeul Kang ◽  
Tae-Wan Jeon ◽  
Woo-Il Kim ◽  
Sun Kyoung Shin ◽  
Jin-Mo Yeon ◽  
...  

Author(s):  
Ahmad A. Tarhini

Patients with locoregionally advanced but surgically operable melanoma continue to carry a high risk of relapse and death despite the best available standard management approaches. Neoadjuvant studies targeting this patient population tested chemotherapy with temozolomide and biochemotherapy (BCT), in which BCT demonstrated high tumor response rates but was eventually abandoned with the failure of BCT to deliver survival benefits in randomized trials of metastatic disease. Smaller neoadjuvant immunotherapy studies with interferon (IFN) alfa and ipilimumab have yielded promising clinical activity and important mechanistic insights and biomarker findings. Newer targeted and immunotherapeutic agents and combinations currently are being translated into the neoadjuvant setting at an accelerated pace and carry significant clinical promise. In drug development, the neoadjuvant approach allows access to blood and tumor tissue before and after initiation of systemic therapy, which allows for the conduct of novel mechanistic and biomarker studies in the circulation and the tumor microenvironment. Such studies may guide drug development and allow for the discovery of predictive biomarkers selected on the basis of their capacity to classify patients according to the degree of benefit from treatment or the risk for significant toxicity.


1997 ◽  
Vol 4 (4) ◽  
pp. 326-334 ◽  
Author(s):  
David J. Sugarbaker ◽  
Jose J. Norberto ◽  
Raphael Bueno

Background Diffuse malignant pleural mesotheliomas (DMPMs) are highly lethal tumors that are becoming more common. Standard management approaches have provided limited effectiveness. Methods The literature on management has been revised, and the authors present their data on outcomes for 120 patients treated with an aggressive trimodality approach. Results An aggressive trimodality approach including extrapleural pneumonectomy followed by chemoradiation produces low mortality and acceptable morbidity. The five-year survival rate in patients with epithelial histology and negative nodes approaches 40%. Conclusions Nodal status and histologic subtype are major predictors for survival in patients with early DMPM. A uniformly accepted staging system would allow comparison of treatment approaches from various institutions. More effective management interventions are required.


1992 ◽  
Vol 26 (1-2) ◽  
pp. 1-10 ◽  
Author(s):  
S. E. Hrudey

Canada's political, economic and geographic make-up have influenced the approaches to hazardous waste management. Split jurisdiction between the federal and provincial governments on environmental issues has made consensus decisions expedient. These consensus approaches combined with some preference for public sector ownership of hazardous waste treatment and disposal facilities distinguish the Canadian system from the hazardous waste regulatory regime in the United States. Because many of the Canadian hazardous waste management guidelines have been recently developed, they may reflect the benefit of learning from experiences elsewhere, both positive and negative.


Blood ◽  
2014 ◽  
Vol 123 (7) ◽  
pp. 974-984 ◽  
Author(s):  
Dragana Milojkovic ◽  
Jane F. Apperley

Leukemia in pregnancy remains a challenging therapeutic prospect. The prevalence is low at ∼1 in 10 000 pregnancies, and as a result data are limited to small retrospective series and case reports, rendering evidence-based recommendations for management strategies difficult. The management of the leukemias in pregnancy requires close collaboration with obstetric and neonatology colleagues as both the maternal and fetal outcomes must be taken into consideration. The decision to introduce or delay chemotherapy must be balanced against the impact on maternal and fetal survival and morbidity. Invariably, acute leukemia diagnosed in the first trimester necessitates intensive chemotherapy that is likely to induce fetal malformations. As delaying treatment in this situation is usually inappropriate, counseling with regard to termination of pregnancy is often essential. For chronic disease and acute leukemia diagnosed after the second trimester, therapeutic termination of the pregnancy is not inevitable and often, standard management approaches similar to those in nongravid patients can be used. Here, the management of the acute and chronic leukemias will be addressed.


Author(s):  
Amy Lustig ◽  
Cesar Ruiz

The purpose of this article is to present a general overview of the features of drug-induced movement disorders (DIMDs) comprised by Parkinsonism and extrapyramidal symptoms. Speech-language pathologists (SLPs) who work with patients presenting with these issues must have a broad understanding of the underlying disease process. This article will provide a brief introduction to the neuropathophysiology of DIMDs, a discussion of the associated symptomatology, the pharmacology implicated in causing DIMDs, and the medical management approaches currently in use.


Sign in / Sign up

Export Citation Format

Share Document